Valeant Subpoenaed: Price Hikes Bring Patient Assistance Scrutiny
This article was originally published in Scrip
Executive Summary
With all of the hoopla on Capitol Hill over Valeant Pharmaceuticals International Inc.'s aggressive pricing practices involving drugs like Isuprel (isoprenaline) and Nitropress (sodium nitroprusside) – whose prices were hiked considerably after the company acquired the medicines from Marathon Pharmaceuticals in February – it was inevitable it wouldn't take long until federal prosecutors got involved.